Publications by authors named "W S York"
The Ovarian Cancer Retrospective European (O'CaRE) study assessed the cumulative impact of high-risk factors on progression-free survival (PFS) and overall survival (OS) following first-line treatment in patients diagnosed with advanced ovarian cancer. Medical records were collected from five European countries (2014 and 2015). Patients were grouped by number of high-risk factors: stage IV diagnosis, no known , interval debulking surgery or no surgery, or visible residual disease.
View Article and Find Full Text PDFPatterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012.
Gynecol Oncol
October 2024
Article Synopsis
- The study analyzed how advanced ovarian cancer patients respond to niraparib maintenance therapy and patterns of disease recurrence.
- Of 314 patients, 190 developed new lesions, primarily in the peritoneum, lymph nodes, and liver, often seeing 1-3 new lesions upon progression.
- Findings suggest that while many patients develop oligometastatic disease at recurrence, further research is needed to assess if local therapies could enhance outcomes when combined with targeted maintenance therapy.
Article Synopsis
- The study aimed to assess the safety and tolerability of an individualized starting dose (ISD) of niraparib in patients with newly diagnosed advanced ovarian cancer who responded to platinum-based chemotherapy.
- An analysis of treatment-emergent adverse events (TEAEs) revealed that common side effects occurred early, with hematologic TEAEs resolving in over 89% of patients within a median duration of about 2 weeks.
- Overall, the niraparib ISD was found to be well tolerated, indicating the importance of close monitoring after starting treatment and helping set patient expectations regarding safety.
Objective: To identify characteristics associated with long-term progression-free survival (≥2 years) in patients with advanced ovarian cancer treated with niraparib first-line maintenance therapy in the phase III PRIMA/ENGOT-OV26/GOG-3012 study.
Methods: In this post hoc analysis of PRIMA, patients randomized to niraparib were grouped based on investigator-assessed progression-free survival (progressive disease/censoring <2 years or ≥2 years after randomization). Variables assessed for predictive value were Eastern Cooperative Oncology Group performance status, International Federation of Gynecology and Obstetrics (FIGO) stage at diagnosis, clinical response to platinum-based chemotherapy, number of prior chemotherapy cycles, primary tumor location, body mass index, categorical age, debulking surgery type, number of baseline target lesions, number of baseline non-target lesions, /homologous recombination-deficiency status, residual disease status, and duration from end of chemotherapy to randomization.
Objective: To evaluate the impact of age on the efficacy and safety of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer with a complete/partial response to first-line platinum-based chemotherapy.
Methods: Post hoc analysis of the phase 3 PRIMA/ENGOT-OV26/GOG-3012 study (NCT02655016). Patients in the intent-to-treat population were categorized according to age at baseline (<65 years vs ≥65 years), and progression-free survival (PFS), safety, and health-related quality of life (HRQOL) were evaluated for each age subgroup (clinical cutoff date, May 17, 2019).